Haemonetics

Q3 2026 Q2 2026 +31.77%Q1 2026 -26.83%Q4 2025 +5.87%Q3 2025 -11.58%Q2 2025 +11.85%Q1 2025 -10.14%Q4 2024 +2.80%Q3 2024 -3.77%Q2 2024 +2.36%Q1 2024 +2.01%Q4 2023 +7.64%Q3 2023 -5.45%Q2 2023 +4.12%Q1 2023 +8.11%Q4 2022 +3.90%Q3 2022 +21.18%Q2 2022 -13.52%Q1 2022 +8.38%Q4 2021 -6.40%Q3 2021 +12.84%Q2 2021 -3.72%Q1 2021 -12.72%Q4 2020 -8.80%Q3 2020 +7.19%Q2 2020 +0.29%Q1 2020 +10.52%Q4 2019 +2.81%Q3 2019 -12.16%Q2 2019 +9.14%Q1 2019 +4.80%Q4 2018 +5.81%Q3 2018 +14.84%Q2 2018 +15.78%Q1 2018 +4.20%Q4 2017 -1.90%Q3 2017 -10.14%Q2 2017 +10.48%Q1 2017 +13.79%Q4 2016 -15.05%Q3 2016 +5.88%Q2 2016 -3.93%Q1 2016 +1.45%Q4 2015 -3.94%Q3 2015 +7.03%Q2 2015 -5.91%Q1 2015 -1.36%Q4 2014 -7.97%Q3 2014 -2.60%Q2 2014 +1.52%Q1 2014 +0.72%Q4 2013 -1.40%Q3 2013 -5.63%Q2 2013 +4.26%Q1 2013 -0.10%Q4 2012 +4.16%Q3 2012 -1.02%Q2 2012 +0.44%Q1 2012 +3.06%Q4 2009 +1.33%Q4 2011 +1.33%Q3 2010 -1.29%Q3 2011 -1.29%Q2 2011 +1.70%Q1 2010 -2.53%Q1 2011 -2.53%Q2 2010 -2.53%Q4 2010 -2.53%

Feb 02, 2021

•

Dec 26, 2020

Haemonetics Q3 2021 Earnings Report

Haemonetics' Q3 2021 financial results were reported, showing revenue decrease but improved profitability driven by Operational Excellence Program and cost management.

Key Takeaways

Haemonetics reported a 7.2% decrease in revenue to $240.4 million for Q3 2021, impacted by COVID-19. However, profitability improved due to the Operational Excellence Program and cost management. The company is progressing with NexSys® and TEG® adoption and investing in innovation.

Q3 revenue decreased by 7% to $240 million.

Earnings per diluted share was $0.62, while adjusted earnings per diluted share was $0.81.

Gross margin was 50.0%, up 60 basis points compared to the prior year.

Operating income was $40.4 million, with an operating margin of 16.8%.